Completed PHASE1 INTERVENTIONAL 3-arm NCT03739931

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade

Sponsor: AstraZeneca

Conditions Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

Interventions Durvalumab mRNA-2752

Updated 28 times since 2018 Last updated: Aug 14, 2025 Started: Nov 27, 2018 Primary completion: Aug 1, 2025 Completion: Aug 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03739931, this PHASE1 trial focuses on Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma and Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma and remains completed. Sponsored by AstraZeneca, it has been updated 28 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

28 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
Sep 2024 — Jun 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

▶ Show 23 earlier versions

Feb 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Apr 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE1
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Jan 2023 [monthly]

Recruiting PHASE1
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1
May 2022 — Jul 2022 [monthly]

Recruiting PHASE1
Apr 2022 — May 2022 [monthly]

Recruiting PHASE1
Jan 2022 — Apr 2022 [monthly]

Recruiting PHASE1
Nov 2021 — Jan 2022 [monthly]

Recruiting PHASE1
Apr 2021 — Nov 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1
Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE1
May 2020 — Jul 2020 [monthly]

Recruiting PHASE1
Nov 2019 — May 2020 [monthly]

Recruiting PHASE1
Jul 2019 — Nov 2019 [monthly]

Recruiting PHASE1
May 2019 — Jul 2019 [monthly]

Recruiting PHASE1
Mar 2019 — May 2019 [monthly]

Recruiting PHASE1
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE1
Dec 2018 — Feb 2019 [monthly]

Recruiting PHASE1

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
ModernaTX, Inc.

Data source: ModernaTX, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Boston, United States , Chicago, United States , Cleveland, United States , Detroit, United States , Haifa, Israel , Melbourne, Australia , Nashville, United States , Nedlands, Australia , New Haven, United States and 11 more locations